Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Frequently asked questions
What sector does Neuren Pharmaceuticals Limited (NURPF) operate in?
Neuren Pharmaceuticals Limited belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Neuren Pharmaceuticals Limited (NURPF) current stock price?
As of the latest data, Neuren Pharmaceuticals Limited stock price is $14.28, with a previous close of $14.28.
What is Neuren Pharmaceuticals Limited (NURPF) current market capitalization?
Neuren Pharmaceuticals Limited market cap is approximately 1.81 billion.
What is Neuren Pharmaceuticals Limited (NURPF) Earnings Per Share (EPS)?
The trailing EPS is $0.10.
What is Neuren Pharmaceuticals Limited (NURPF) Price-to-Earnings (P/E) ratio?
Neuren Pharmaceuticals Limited current P/E ratio is 142.77.
What is Neuren Pharmaceuticals Limited (NURPF) EBITDA?
Neuren Pharmaceuticals Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 2.73 million.
Does Neuren Pharmaceuticals Limited (NURPF) pay dividends?
Yes. Neuren Pharmaceuticals Limited pays semiannual dividends with an annualized yield of 1.5% and an estimated annual payout of $0.21 per share.
When is the next ex-dividend date for Neuren Pharmaceuticals Limited (NURPF)?
The next ex-dividend date is scheduled for March 17, 2027.
What is Neuren Pharmaceuticals Limited (NURPF) beta (volatility) score?
Neuren Pharmaceuticals Limited has a beta of 1.567, suggesting it is more volatile than the market.
